All In Biotech

Drug Trial Radar · NCT07625644

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Aug 4, 2026

Primary completion

Jan 2030

Study completion Jun 2031

Sponsor

Lead sponsor
SystImmune Inc.Industry
Sponsor type
Industry
First posted
Jun 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Conditions

  • Small Cell Lung Cancer Extensive Stage
  • Small-cell Lung Cancer
  • Small Cell Carcinoma
  • Sclc
  • SCLC,Extensive Stage
  • Lung Cancer
  • Lung Cancer Metastatic
  • Lung Cancer Stage IV

Interventions

  • BL-M14D1 and AtezolizumabDrug

    BL-M14D1 administered in combination with atezolizumab. BL-M14D1 will be given intravenously at the protocol-specified dose and schedule. Atezolizumab will be administered intravenously according to the approved dosing regimen.

  • Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and LurbinectedinDrug

    Carboplatin and etoposide will be administered intravenously in combination with atezolizumab for induction therapy, followed by maintenance treatment with atezolizumab with or without lurbinectedin per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)Time frame: Up to approximately 2 years

Locations

84 sites in 16 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • OPN Healthcare

    Glendale, California · Recruiting

  • MemorialCare Todd Cancer Institute

    Long Beach, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Total Health and Research Center

    Miami, Florida · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • One Clinical Research

    Nedlands, Australia · Not yet recruiting

  • Canberra Hospital

    Garran, Australian Capital Territory, Australia · Not yet recruiting

  • Tasman Oncology

    Southport, Queensland, Australia · Not yet recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Not yet recruiting

  • MHAT Dr. Tota Venkova

    Gabrovo, Bulgaria · Not yet recruiting

  • MHAT Heart and Brain

    Pleven, Bulgaria · Not yet recruiting

  • Medical Centre FutureMeds

    Plovdiv, Bulgaria · Not yet recruiting

  • Complex Oncology Center

    Plovdiv, Bulgaria · Not yet recruiting

  • MHAT Pulmed

    Plovdiv, Bulgaria · Not yet recruiting

  • UMHAT Sveti Ivan Rilski

    Sofia, Bulgaria · Suspended

  • MHAT Serdikamed

    Sofia, Bulgaria · Not yet recruiting

  • Arthur Child Cancer Centre

    Calgary, Alberta, Canada · Not yet recruiting

  • University of Sherbrooke

    Greenfield Park, Quebec, Canada · Not yet recruiting

  • Nemocnice České Budějovice, a.s.

    České Budějovice, Czechia · Not yet recruiting

  • Nemocnice Agel Vítkovice

    Ostrava, Czechia · Not yet recruiting

  • Fakultní nemocnice Ostrava (FN Ostrava)

    Ostrava-Poruba, Czechia · Not yet recruiting

  • General University Hospital in Prague

    Prague, Czechia · Not yet recruiting

  • Organization Centre Hospitalier Intercommunal de Creteil (CHIC) - Centre de Recherche Clinique (CRC) (Clinical Research Center)

    Créteil, France · Not yet recruiting

  • CLB - Centre Léon Bérard

    Lyon, France · Not yet recruiting

  • IPC - lnstitut Paoli-Calmettes

    Marseille, France · Not yet recruiting

  • Universite Pierre et Marie Curie (UPMC) - Center de Recherche des Cordeliers (CRC)

    Paris, France · Not yet recruiting

  • ICO - L'Institut de Cancérologie de L'Ouest

    Saint-Herblain, France · Not yet recruiting

  • Gustave Roussy

    Villejuif, France · Not yet recruiting

  • LTD High Technology Hospital Medcenter

    Tbilisi, Georgia · Recruiting

  • Ltd New Hospitals

    Tbilisi, Georgia · Recruiting

  • Pineo Medical Ecosystem LtD

    Tbilisi, Georgia · Recruiting

  • LLC Todua Clinic

    Tbilisi, Georgia · Recruiting

  • The First Medical Clinic LLC

    Tbilisi, Georgia · Recruiting

  • Caucasus Medical Centre

    Tbilisi, Georgia · Recruiting

  • Lungenklinik/Lungenkrebszentrum Köln-Merheim

    Cologne, Germany · Not yet recruiting

  • KEM | Evangelische Kliniken Essen Mitte gGmbH

    Essen, Germany · Not yet recruiting

  • Krankenhaus Martha-Maria Halle-Dölau

    Halle, Germany · Not yet recruiting

  • Henry Dunant Hospital Center

    Athens, Greece · Not yet recruiting

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.